Abstract
This study uses the results of the FOURIER trial to assess the current cost-effectiveness of PCSK9 inhibitors over the lifetime analytic horizon for patients with atherosclerotic cardiovascular disease in the United States.
MeSH terms
-
Antibodies, Monoclonal / economics*
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Anticholesteremic Agents / economics*
-
Anticholesteremic Agents / therapeutic use
-
Cardiovascular Diseases / prevention & control
-
Cholesterol, LDL / blood*
-
Cost-Benefit Analysis
-
Drug Costs
-
Drug Therapy, Combination
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Hypercholesterolemia / drug therapy*
-
Hypercholesterolemia / economics
-
PCSK9 Inhibitors*
-
Quality-Adjusted Life Years
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Anticholesteremic Agents
-
Cholesterol, LDL
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
PCSK9 Inhibitors
-
PCSK9 protein, human
-
evolocumab